Special Feature

User Panel

My Panel

My Panel

Bookmark Science Articles

Recent News
Bookmark / Share This Science Site

[Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases]

[Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

  • Abstract Text of This Paper
  • Journal Published
  • MeSH Keywords of This Abstract
  • Chemicals and Substances Used in this Paper
  • Grants and Granting Agency of this Research
  • Database Accession Numbers Used in this Paper
  • Related Papers
  • Related Research Tags
  • Rate this Research Paper
  • [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Abstract Text:

    t asakuraT Asakura,t jikuyaT Jikuya,n atsumiN Atsumi,y teradaY Terada,y sakakibaraY Sakakibara,t mitsuiT Mitsui,

    Prosthetic valve thrombosis is associated with high mortality. Thrombolytic therapy is a promising alternative to valve replacement in the management of prosthetic valve thrombosis. To determine the efficacy and safety of thrombolytic therapy for thrombosed Björk-Shiley aortic valve prosthesis, 4 patients who received urokinase intravenously for this disorder were analyzed. In 3 patients, the successful outcome was sustained in that they remained asymptomatic and did not require operative intervention during follow-up, which ranged from 17 to 101 months. In one patient clinical signs of mild congestive heart failure occurred. This patient was surgically treated by thrombectomy and debridement of the prosthetic valve. Failure of urokinase treatment to resolve the thrombus after 1 week indicates that tissue overgrowth or fibrous, organized thrombus is the cause of prosthetic malfunction. Surgical intervention for this problem should be considered only after thrombolytic therapy has been tried and has failed. Our experience with urokinase treatment of thrombosis of aortic Björk-shiley prostheses indicates that this form of treatment should always be applied before surgical intervention. We also attempted to define the optimum protocol of fibrinolytic therapy by clinical evaluation. A protocol for the safe treatment of thrombosed valve is urokinase in initially administered in the doses as 960,000 units for 24 hours, then followed by a maintenance infusion at the half dose every 24 or 48 hours later. Thrombolytic therapy should be continued for 1 week at least to prevent rethrombosis even normalization of valve function was documented clinically. Simultaneous heparin infusion of 10,000 units for 24 hours is then started to replaced by warfarin treatment adjusted to obtain optimal prothrombin times.(ABSTRACT TRUNCATED AT 250 WORDS)

    [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Publishing Authors By Initials

    t asakuraT Asakura,t jikuyaT Jikuya,n atsumiN Atsumi,y teradaY Terada,y sakakibaraY Sakakibara,t mitsuiT Mitsui,

    For similar enzymes and coenzymes: enzymes: hydrolases: peptide hydrolases: endopeptidases: serine endopeptidases: urinary plasminogen activator research abstracts see: enzymes and coenzymes: enzymes: hydrolases: peptide hydrolases: endopeptidases: serine endopeptidases: urinary plasminogen activator research

    PUBMED ID PMID:

    MEDLINE DATE:

    [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Journal Published:

    PUBLICATION TYPE: Journal Article

    Journal: [Zasshi] [Journal]. Nihon Ky?bu Geka Gakkai

    VOLUME: 42

    Page Numbers: 1214-21

    Journal Abbreviation:

    ISSN: 0369-4739

    DAY: 14

    MONTH: Aug

    YEAR: 1994

    [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Information

    Number of References:

    LANGUAGE: jpn

    NlmUniqueID: 19130180

    [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Keywords Mesh Terms:

    KEYWORDS: Urinary Plasminogen Activator

    MESH TERMS: therapeutic use

    Chemical & Substance for Abstract: [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases] Information

    Substance Name: Urinary Plasminogen Activator

    Registry Number: EC 3.4.21.73

    Grant and Affiliation Information for [Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases]

    AFFILIATION: Department of Cardiovascular Surgery, University of Tsukuba Hospital, Japan.

    Country: JAPAN

    JAPAN Research PublicationJAPAN Research Publication

    AGENCY:

    GRANT:

    ACRONYM:

    MEDLINETA: Nippon Kyobu Geka Gakkai Zassh

    REFSOURCE:

    DATABASENAME:

    ACCESSION NUMBER:

    Number Hits: 0

    Thrombolytic therapy of thrombosed Björk-Shiley aortic valve prosthesis--report of four cases Related Publications

     

    Molecular Station USER Menu

    Welcome to Molecular Station!

    You have to register before you can post on our forums or use our advanced features. Register Now! Its Free and Fast!

    Already registered? Login now below.

    User Name:

    Password:

    Already registered and Forgot your password? Click below to recover it.

    Recover Lost Password

    Join now - it's fast and free!

    Molecular Station is THE largest network of researchers, scientists and science lovers anywhere!

    Research Terms of Usage and Disclaimer
    Home
    Features

    Protocols

    DNA Forum

    Science Forum

    DNA Forum
    Biology Forum

    Science News


    [CaRP] XML error: Invalid document end at line 2

    For more click here:Science News